Home > Publications Database > Breaking barriers: noncanonical inflammasome executes blood-brain barrier disruption. > print

001     271151
005     20250127091637.0
024 7 _ |a pmc:PMC11306631
|2 pmc
024 7 _ |a 10.1038/s41392-024-01921-1
|2 doi
024 7 _ |a pmid:39112463
|2 pmid
024 7 _ |a 2095-9907
|2 ISSN
024 7 _ |a 2059-3635
|2 ISSN
024 7 _ |a altmetric:166082421
|2 altmetric
037 _ _ |a DZNE-2024-01019
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Dichgans, Martin
|0 P:(DE-2719)2000030
|b 0
|e First author
245 _ _ |a Breaking barriers: noncanonical inflammasome executes blood-brain barrier disruption.
260 _ _ |a London
|c 2024
|b Macmillan Publishers, part of Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1723723294_26248
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Inflammasomes
|2 NLM Chemicals
650 _ 7 |a NLR Family, Pyrin Domain-Containing 3 Protein
|2 NLM Chemicals
650 _ 2 |a Blood-Brain Barrier: metabolism
|2 MeSH
650 _ 2 |a Blood-Brain Barrier: immunology
|2 MeSH
650 _ 2 |a Inflammasomes: metabolism
|2 MeSH
650 _ 2 |a Inflammasomes: genetics
|2 MeSH
650 _ 2 |a Inflammasomes: immunology
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a NLR Family, Pyrin Domain-Containing 3 Protein: genetics
|2 MeSH
650 _ 2 |a NLR Family, Pyrin Domain-Containing 3 Protein: metabolism
|2 MeSH
650 _ 2 |a NLR Family, Pyrin Domain-Containing 3 Protein: immunology
|2 MeSH
700 1 _ |a Neher, Jonas J
|0 P:(DE-2719)2811021
|b 1
|u dzne
700 1 _ |a Asare, Yaw
|0 0000-0002-8946-5650
|b 2
773 _ _ |a 10.1038/s41392-024-01921-1
|g Vol. 9, no. 1, p. 213
|0 PERI:(DE-600)2886872-9
|n 1
|p 213
|t Signal transduction and targeted therapy
|v 9
|y 2024
|x 2095-9907
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/271151/files/DZNE-2024-01019.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/271151/files/DZNE-2024-01019.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:271151
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2000030
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2811021
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-27
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SIGNAL TRANSDUCT TAR : 2022
|d 2023-10-27
915 _ _ |a IF >= 30
|0 StatID:(DE-HGF)9930
|2 StatID
|b SIGNAL TRANSDUCT TAR : 2022
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-05-02T09:09:38Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-05-02T09:09:38Z
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-27
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-05-02T09:09:38Z
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-05-02T09:09:38Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-27
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 0
920 1 _ |0 I:(DE-2719)1210012
|k AG Neher
|l Neuroimmunology and Neurodegenerative Disease
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000022
980 _ _ |a I:(DE-2719)1210012
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21